p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel

Cancer Research

Volumn 57, Issue 5, 1997, Pages 870-874

  Debernardis, Domizia ^b   Siré, Eva Graniela ^a   De Feudis, Paola ^a   Vikhanskaya, Faina ^b   Valenti, Monica ^b   Russo, Patrizia ^b   Parodi, Silvio ^b   D'Incalci, Maurizio ^a   Broggini, Massimo ^a  

^a Molecular Pharmacology Unit   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; ETIOLOGY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; OVARIAN NEOPLASMS; PACLITAXEL; PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031036695     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Gregory, R. E., and DeLisa, A. F. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin. Pharm., 12: 401-415, 1993.
2. McGuire, W. P. Taxol: a new drug with significant activity as a salvage therapy in advanced epithelial ovarian carcinoma. Gynecol. Oncol., 51: 78-85, 1993.
3. Horwitz, S. B. Mechanism of action of taxol. Trends. Pharmacol. Sci., 13: 134-136, 1992.
4. Rose, W. C. Taxol: a review of its preclinical in vivo antitumor activity. Anticancer Drugs, 3: 311-321, 1992.
5. Donaldson, K. L., Goolsby, G. L., Kiener, P. A., and Wahl, A. F. Activation of p34cdc2 coincident with Taxol-induced apoptosis. Cell Growth & Differ., 5: 1041-1050, 1994.
6. Donaldson, K. L., Goolsby, G. L., and Wahl, A. F. Cytotoxicity of the anticancer agents cisplatin and Taxol during cell proliferation and the cell cycle. Int. J. Cancer, 57: 847-855, 1994.
7. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
8. Lane, D. P. Cancer: p53, guardian of the genome. Nature (Lond.), 358: 15-16, 1992.
9. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
10. 1 arrest in human cancer cells. Cancer Res., 55: 5187-5190, 1995.
11. Enoch, T., and Norbury, C. Cellular responses to DNA damage: cell-cycle check-points, apoptosis and the roles of p53 and ATM. Trends Biochem. Sci., 20: 426-430, 1995.
12. Wahl, A. F., Donaldson, K. L., Fairchild, C., Lee, F. Y., Foster, S. A., Demers, G. W., and Galloway, D. A. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat. Med., 2: 72-79, 1996.
13. Wu, G. S., and El-Deiry, W. S. p53 and chemosensitivity. Nat. Med., 2. 225-226, 1996.
14. Graniela Siré, E. A., Vikhanskaya, F., and Broggini, M. Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. Ann. Oncol., 6: 589-593, 1995.
15. Tishler, R. B., Lamppu, D. M., Park, S., and Price, B. D. Microtubule-active drugs Taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. Cancer Res., 55: 6021-6025, 1995.
16. Vikhanskaya, F., Erba, E., D'Incalci, M., and Broggini, M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res., 22: 1012-1017, 1994.
17. Chirgwin, J. M., Przybyla, A. E., MacDonald, R. J., and Rutter, W. J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry, 18: 5294-5299, 1979.
18. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
19. Bertrand, R., Kohn, K. W., Solary, E., and Pommier, Y. Detection of apoptosis-associated DNA fragmentation using a rapid quantitative filter elution assay. Drug Dev. Res., 34: 138-144, 1995.
20. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
21. Lowe, S. W. Cancer therapy and p53. Curr. Opin. Oncol., 7: 547-553, 1995.
22. Blagosklonny, M. V., Schulte, T. W., Nguyen, P., Mimnaugh, E. G., Trepel, J., and Neckers, L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res., 55: 4623-4626, 1995.
23. Blagosklonny, M. V., Schulte, T. W., Nguyen, P., Trepel, J., and Neckers, L. Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer Res., 56: 1851-1854, 1996.
24. Vikhanskaya, F., D'Incalci, M., and Broggini, M. Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int. J. Cancer, 61: 397-401, 1995.
25. Woods, C. M., Zhu, J., McQueney, P. A., Bollag, D., and Lazarides, E. Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol. Med., 1: 506-526, 1995.
26. Liu, Y., Bhalla, K., Hill, C., and Priest, D. G. Evidence for involvement of tyrosine phosphorylation in taxol-induced apoptosis in a human ovarian tumor cell line. Biochem. Pharmacol., 48: 1265-1272, 1994.
27. Havrilesky, L. J., Elbendary, A., Hurteau, J. A., Whitaker, R. S., Rodriguez, G. C., and Berchuck, A. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet. Gynecol., 85: 1007-1010, 1995.